Latest news with #ArcturusTherapeutics
Business Insider
2 days ago
- Business
- Business Insider
Citi Keeps Their Buy Rating on Arcturus Therapeutics (ARCT)
Citi analyst Yigal Nochomovitz maintained a Buy rating on Arcturus Therapeutics (ARCT – Research Report) today and set a price target of $47.00. The company's shares closed today at $12.54. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Nochomovitz is a 4-star analyst with an average return of 3.5% and a 38.98% success rate. Nochomovitz covers the Healthcare sector, focusing on stocks such as Arcturus Therapeutics, Summit Therapeutics, and Arvinas Holding Company. Arcturus Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $51.63.
Ottawa Citizen
02-06-2025
- Health
- Ottawa Citizen
Deonandan: Cancelling funding for mRNA vaccine is both risky and foolish
Article content More challenging is the lead time for manufacturing these traditional vaccines. At the very least, many months are needed, which is why the seasonal flu vaccine is often a poor match to circulating strains, resulting in middling efficacy. If an H5N1 pandemic is in our near future, it will not be possible to manufacture sufficient doses of the currently licensed vaccines quickly enough to protect everyone. Article content The only proven vaccine technology capable of the kind of rapid production needed to quell a sudden pandemic is the mRNA platform. Five years of refinement over the course of the COVID pandemic have afforded Moderna and Pfizer a kind of confident fluency in their development and deployment acumen. Other companies, such as Arcturus Therapeutics, CureVac, and Sanofi have since adopted the technology as well. Article content Keeping up with mutations Article content Article content Another consideration is viral mutation. If H5N1 makes the mutational leap to sustained human-to-human transmission, it will be because its genetic makeup will have changed slightly enough to make that happen. In other words, the virus will be measurably different from that used to create the currently licensed formulations, some of which are limitedly stockpiled by governments. Article content The mRNA platform will be needed to quickly pivot to targeting the new viral formulation. It can do so with much more adeptness and fluidity than the lumbering egg- and cell-incubated vaccines currently stockpiled. Remember: the first COVID mRNA vaccine was finalized just 48 hours after scientists sequenced the genetic code of the virus that causes COVID. Article content RFK Jr.'s decision to cancel this funding is shortsighted and seemingly driven by skewed and nonsensical antivax perceptions. It comes at a time when Moderna's investigational pandemic influenza vaccine, called 'mRNA-1018' had already demonstrated safety through early clinical trials. Article content Perhaps this is an opportunity for other countries — such as Canada — to fill the funding void and claim the financial and societal benefits of this transformational technology.
Yahoo
13-05-2025
- Business
- Yahoo
Arcturus Therapeutics Holdings Inc (ARCT) Q1 2025 Earnings Call Highlights: Strategic Focus and ...
Revenue: $29.4 million for Q1 2025, down from $38 million in Q1 2024. Research and Development Expenses: $34.9 million for Q1 2025, down from $53.6 million in Q1 2024. General and Administrative Expenses: $11.3 million for Q1 2025, down from $14.9 million in Q1 2024. Net Loss: Approximately $14.1 million or $0.52 per diluted share for Q1 2025. Cash and Cash Equivalents: $273.8 million as of March 31, 2025, down from $293.9 million as of December 31, 2024. Cash Runway: Extended to Q1 2028. Warning! GuruFocus has detected 4 Warning Signs with ARCT. Release Date: May 12, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) is advancing its mRNA therapeutics pipeline with significant progress in clinical trials for cystic fibrosis (ARCT-032) and ornithine transcarbamylase deficiency (ARCT-810). The company received EU approval for its self-amplifying mRNA COVID-19 vaccine, KOSTAIVE, and an initial milestone payment from its global vaccine partner, CSL. Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) has extended its cash runway until the first quarter of 2028, allowing it to focus on its critical CF and OTC programs. The company has received US FDA fast track designation for its SA mRNA vaccine candidate for pandemic influenza A (H5N1), ARCT-2304. Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) is in a strong financial position with cash and cash equivalents of $273.8 million as of March 31, 2025. Revenues for the first quarter of 2025 decreased to $29.4 million from $38 million in the same period of 2024, primarily due to lower development milestone revenues. Research and development expenses decreased to $34.9 million from $53.6 million in the comparable period last year, reflecting lower manufacturing costs but also indicating reduced activity in some areas. The company reported a net loss of approximately $14.1 million for the first quarter of 2025, highlighting ongoing financial challenges. Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) has made the decision to focus its research and development expenditures exclusively on its CF and OTC programs, potentially limiting diversification. There are no anticipated milestone payments from the UK or US filings for KOSTAIVE until 2028, which may impact short-term financial expectations. Q: Could you provide more details on the changes made to extend the cash runway and potential incoming cash flows? A: Andrew Sassine, CFO, explained that the decision to focus on the two most critical programs, CF and OTC, involved cost reductions, including eliminating early development R&D programs and consolidating facilities. This strategic focus, along with conservative cash burn guidance, contributed to extending the cash runway to 2028. Q: Regarding the KOSTAIVE vaccine, what are the potential milestones related to UK and US approvals? A: Joseph Payne, CEO, stated there are no milestones associated with UK or US approvals. However, there is a milestone for the first US revenues from KOSTAIVE, anticipated around 2028, assuming approval in 2026. Q: What is the expected size and success criteria for the ARCT-032 interim readout? A: Joseph Payne, CEO, mentioned the interim data will likely involve 6 to 9 subjects from two cohorts. Success criteria include achieving reasonable safety and tolerability over 28 daily administrations and a 3% improvement in FEV (lung function), which would justify advancing the program. Q: How does ARCT-032 differ from competitor mRNA programs for cystic fibrosis? A: Joseph Payne, CEO, highlighted that ARCT-032 uses Arcturus's proprietary LUNAR lipid nanoparticle delivery technology and highly purified mRNA, which may enhance safety and tolerability compared to competitors. Q: Are there any plans for an accelerated approval pathway for ARCT-032? A: Joseph Payne, CEO, indicated that if the phase 2 data is excellent, discussions with regulators about accelerating the approval pathway would be warranted, especially given the significant unmet medical need in cystic fibrosis. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
Washington Post
12-05-2025
- Business
- Washington Post
Arcturus Therapeutics: Q1 Earnings Snapshot
SAN DIEGO — SAN DIEGO — Arcturus Therapeutics (ARCT) on Monday reported a loss of $14.1 million in its first quarter. On a per-share basis, the San Diego-based company said it had a loss of 52 cents. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of $1.58 per share.
Yahoo
21-03-2025
- Business
- Yahoo
CSL initiated with an Overweight at Morgan Stanley
Morgan Stanley initiated coverage of CSL (CSLLY) with an Overweight rating and A$313 price target A 'solid revenue growth outlook' and margin recovery for CSL Behring underpin group EPS growth of about 13% per year over the next three years, the analyst tells investors. Easily identify stocks' risks and opportunities. Discover stocks' market position with detailed competitor analyses. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders' Hot Stocks on TipRanks >> Read More on CSLLY: Questions or Comments about the article? Write to editor@ Arcturus Therapeutics and CSL's Kostaive COVID-19 vaccine approved in Europe CSL, Arcturus Therapeutics announce European Commission approval for Kostaive CSL Limited Earnings Call Highlights Growth and Challenges CSL Limited Reports Strong Half-Year Financial Performance Sign in to access your portfolio
